|Aerie Pharmaceuticals Inc -- USA Stock|| |
USD 64.85 0.25 0.38%
Co-Founder and Chief Scientific Officer
Dr. Casey C. Kopczynski, Ph.D., is Chief Scientific Officer and CoFounder at Aerie Pharmaceuticals, Inc. From 2002 to 2005, he was the Managing Partner at Biotech Initiative, LLC, a consulting practice dedicated to emerging biotech companies. He was also previously the Vice President of Research at Ercole Biotech, Inc. from 2003 to 2004, a company developing drugs for the treatment of cancer, inflammation and orphan genetic diseases. Prior to Ercole Biotech, Inc., Dr. Kopczynski was Director of Research and a founding member of the scientific staff at Exelixis, Inc. from 1996 to 2002
Age: 54 Founder Since 2005 Ph.D
Kopczynski received his PhD in Molecular, Cellular and Developmental Biology from Indiana University and was a Jane Coffin Childs Research Fellow at the University of California, Berkeley.
The company has return on total asset (ROA)
of (29.43) %
which means that it has lost $29.43 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (128.08) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 123.69 M in liabilities with Debt to Equity (D/E) ratio of 66.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Aerie Pharmaceuticals Inc has Current Ratio of 22.0 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Aerie Pharmaceuticals, Inc., a clinicalstage pharmaceutical company, focuses on the discovery, development, and commercialization of firstinclass therapies for the treatment of glaucoma and other eye diseases. Aerie Pharmaceuticals Inc (AERI) is traded on NASDAQ General Markets in USA. It is located in NORTH CAROLINA, U.S.A and employs 70 people. Aerie Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.